|
|
Profile
|
Delegates :
Kohichiro Yoshino |
|
Incorporated :
April 10 , 2003 |
Paid in Capital :
3075 Million yen |
Employees :
58 人 |
Address :
BMA 3F 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 Japan HYOGO
〒6500047
|
TEL/FAX :
+81-78-302-7039 / +81-78-302-6665 |
URL：
http://www.carnabio.com/english/ |
Attachment :
|
Mission/Background :
Carna Biosciences, Inc. was established in 2003 as a spin-off from research division of Organon, and listed on Tokyo Securities Exchange JASDAQ Growth (code 4572) in March, 2008. In April, 2008, we established CarnaBio USA, Inc. in the USA to enhance marketing capability of our drug discovery support business in North America.
At Drug Discovery and Development business, we are focused on the discovery of kinase inhibitors to treat serious unmet medical needs in oncology and autoimmune diseases. We successfully out-licensed our programs to Janssen Biotech in 2015 and to Sierra Oncology in 2016.
At Drug Discovery Support business, we provide kinase proteins, assay-kits, profiling/screening services, and cell-based assays to pharmaceutical companies and academia to support their kinase inhibitor research, taking advantage of our drug discovery platform technology advanced through our proprietary drug discovery research.
|
|
Technology & Business
|
At Drug Discovery and Development business, we conduct research and development of small molecule kinase inhibitors discovered in-house or in collaboration with academia. We have a chemical library consists of high quality molecules generated in-house and reproductive assays to advance our researcht. Our drug discovery programs targeting cancer include CDC7 inhibitor program out-licensed to Sierra Oncology, TNIK inhibitor program targeting cancer stem cells developed in collaboration with the National Cancer Center, and a program targeting leukemic stem cells developed in collaboration with Hiroshima University. We also conduct research of kinase inhibitors targeting autoimmune diseases and neurodegenerative diseases.
At Drug Discovery Support business, we offer 357 kinds of kinase proteins, 323 kinds of profiling and screening services, 335 kinds of assay kits, crystallography service provided by SARomics Biostructures, and cell-based assay service provided by ACD, CAI, and NTRC (as of April 2017).
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Manufacture and sale of kinase proteins
|
Service/Marketing
|
Manufacture and sell 357 kinds of kinase proteins including biotinylated kinases suited for measuring using devices.
|
Sales increase especially in North America
|
Profiling and screening services
|
Service/Marketing
|
Assay kinase inhibitory activity and selectivity of customers’ chemical compounds.
|
Sales increase especially in North America
|
Cell-based assay services
|
Service/Marketing
|
Provide cell-based assay services to evaluate kinase inhibitory activity in cells in collaboration with partners.
|
Sales increase in global market
|
Research and development of low molecule targeted drugs (kinase inhibitors) and out-license of drug discovery pipeline
|
Discovery
|
TNIK inhibitor, CDC7 inhibitor, a program for leukemia, a program targetingneurodegenerative diseases
|
Initiation of clinical studies
|
|
|
|
|
|
Highlights
|
In May 2016, we out-licensed our CDC7 inhibitor program to Sierra Oncology in Canada (renamed from ProNAi). The program is under development by Sierra to initiate clinical studies. Under the terms of the agreement, aggregate milestone payment including upfront payment is expected to be $270 million. We will also receive single-digit tiered royalties on the net sales of the product successfully developed.
|
|
Alliance strategy
|
We conduct out-licensing activities for our pipeline targeting cancer, autoimmune and neurodegenerative diseases. All programs are currently under pre-clinical stage. We have programs already out-licensed, programs that we look for licensing partner after in-house clinical studies, programs that we look for licensing partner after pre-clinical studies, and programs that we seek for entering an out-licensing agreement after conducting pre-clinical studies in collaboration with a pharmaceutical company.
|
|
|